FindTrial
Sign In

Comparing different antibody detection test formats in the diagnosis of patients with Autoimmune Diseases

Antinuclear Antibodies in the diagnosis of Systemic Autoimmune Rheumatic Diseases: Sequential or Parallel testing?

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/01/049127
Enrollment
7956
Registered
2023-01-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M30-M36- Systemic connective tissue disorders

Interventions

None listed

Sponsors

INSTITUTIONAL PG GRANT, KASTURBA MEDICAL COLLEGE, MANIPAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Consecutive patients of both genders who present to Kasturba Hospital, Manipal with suspicion of connective tissue disease (including clinical diagnosis and duration of illness) and tested for antinuclear antibodies will be included in the study.

Exclusion criteria

Exclusion criteria: Patients tested for autoantibodies other than antinuclear antibodies and patients previously diagnosed with connective tissue disorders and tested for antinuclear antibodies will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
The frequency and sequence in which the tests are requested, as well as the benefits, if any, of parallel testing and / or need of any modification of the existing Immunoblot panel for detection of antinuclear antibodies can be analyzed for better patient management.Timepoint: 18 months—

Secondary

MeasureTime frame
Document the presence of rare auto-antibody patterns seen in Indirect immunofluorescence.Timepoint: 18 months—

Countries

India

Contacts

Public ContactDR SHASHIDHAR V

KASTURBA MEDICAL COLLEGE, MANIPAL

shashidhar.v@manipal.edu08202922717

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026